Zhang Yuntao, Tan Wenjie, Lou Zhiyong, Huang Baoying, Zhou Weimin, Zhao Yuxiu, Zhang Jin, Liang Hongyang, Li Na, Zhu Xiujuan, Ding Ling, Guo Yancen, He Zhenyu, He Yao, Wang Zhanhui, Ma Bo, Ma Meng, Zhao Suhua, Chang Zhen, Zhao Xue, Zheng Xiaotong, Wu Guizhen, Wang Hui, Yang Xiaoming
China National Biotec Group Company Limited, Beijing 100024, China.
National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Vaccines (Basel). 2022 Jun 16;10(6):956. doi: 10.3390/vaccines10060956.
It has been reported that the novel coronavirus (COVID-19) has caused more than 286 million cases and 5.4 million deaths to date. Several strategies have been implemented globally, such as social distancing and the development of the vaccines. Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants have appeared, such as Alpha, Beta, Gamma, Delta, and Omicron. With the rapid spread of the novel coronavirus and the rapidly changing mutants, the development of a broad-spectrum multivalent vaccine is considered to be the most effective way to defend against the constantly mutating virus. Here, we evaluated the immunogenicity of the multivalent COVID-19 inactivated vaccine. Mice were immunized by multivalent COVID-19 inactivated vaccine, and the neutralizing antibodies in serum were analyzed. The results show that HB02 + Delta + Omicron trivalent vaccine could provide broad spectrum protection against HB02, Beta, Delta, and Omicron virus. Additionally, the different multivalent COVID-19 inactivated vaccines could enhance cellular immunity. Together, our findings suggest that the multivalent COVID-19 inactivated vaccine can provide broad spectrum protection against HB02 and other virus variants in humoral and cellular immunity, providing new ideas for the development of a broad-spectrum COVID-19 vaccine.
据报道，截至目前，新型冠状病毒（COVID-19）已导致超过2.86亿例感染和540万人死亡。全球已实施了多种策略，如社交 distancing 和疫苗研发。出现了几种严重急性呼吸综合征冠状病毒2（SARS-CoV-2）变体，如 Alpha、Beta、Gamma、Delta 和 Omicron。随着新型冠状病毒的迅速传播和不断变化的突变体，开发广谱多价疫苗被认为是抵御不断变异病毒的最有效方法。在此，我们评估了多价 COVID-19 灭活疫苗的免疫原性。用多价 COVID-19 灭活疫苗免疫小鼠，并分析血清中的中和抗体。结果表明，HB02 + Delta + Omicron 三价疫苗可对 HB02、Beta、Delta 和 Omicron 病毒提供广谱保护。此外，不同的多价 COVID-19灭活疫苗可增强细胞免疫。总之，我们的研究结果表明，多价 COVID-19 灭活疫苗可在体液免疫和细胞免疫中对 HB02 和其他病毒变体提供广谱保护，为开发广谱 COVID-19 疫苗提供了新思路。
Zotero 插件